Literature DB >> 22234979

The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study.

N A Koloski1, M Jones, J Kalantar, M Weltman, J Zaguirre, N J Talley.   

Abstract

OBJECTIVE: Psychological factors are known to be associated with functional gastrointestinal disorders (FGIDs) including irritable bowel syndrome (IBS) and functional dyspepsia (FD). No prospective studies have evaluated whether it is the brain (eg, via anxiety) that drives gut symptoms, or whether gut dysfunction precipitates the central nervous system features such as anxiety. In a 12-year longitudinal, prospective, population-based study, we aimed to determine the directionality of the brain-gut mechanism in FGIDs.
DESIGN: Participants (n=1775) were a random population sample from Australia who responded to a survey on FGIDs in 1997 and agreed to be contacted for future research; 1002 completed the 12-year follow-up survey (response rate =60%), with 217, 82 and 45 people meeting Rome II for new onset FGIDs, IBS and FD, respectively. Anxiety and depression were measured using the Delusions Symptom States Inventory at baseline and follow-up.
RESULTS: Among people free of a FGID at baseline, higher levels of anxiety (OR 1.11; 95% CI 1.03 to 1.19, p=0.006) but not depression at baseline was a significant independent predictor of developing new onset FGIDs 12 years later. Among people who did not have elevated levels of anxiety and depression at baseline, those with a FGID at baseline had significantly higher levels of anxiety and depression at follow-up (mean difference coefficient 0.76, p<0.001 and 0.30, p=0.01 for anxiety and depression, respectively). In IBS higher levels of anxiety and depression at baseline were predictive of IBS at follow-up, while only depression was predictive of FD at follow-up.
CONCLUSIONS: The central nervous system and gut interact bidirectionally in FGIDs.

Entities:  

Mesh:

Year:  2012        PMID: 22234979     DOI: 10.1136/gutjnl-2011-300474

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  129 in total

Review 1.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

2.  Women and functional dyspepsia.

Authors:  Kate Napthali; Natasha Koloski; Marjorie M Walker; Nicholas J Talley
Journal:  Womens Health (Lond)       Date:  2016-02-22

3.  Does irritable bowel syndrome increase the risk of interstitial cystitis/bladder pain syndrome? A cohort study of long term follow-up.

Authors:  Kun-Min Chang; Ming-Huei Lee; Hsuan-Hung Lin; Shang-Liang Wu; Huei-Ching Wu
Journal:  Int Urogynecol J       Date:  2021-02-23       Impact factor: 2.894

Review 4.  New treatments for IBS.

Authors:  Magnus Halland; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-13       Impact factor: 46.802

Review 5.  Treatment of abdominal pain in irritable bowel syndrome.

Authors:  Tim Vanuytsel; Jan F Tack; Guy E Boeckxstaens
Journal:  J Gastroenterol       Date:  2014-05-21       Impact factor: 7.527

6.  Sleep measures predict next-day symptoms in women with irritable bowel syndrome.

Authors:  Diana Taibi Buchanan; Kevin Cain; Margaret Heitkemper; Robert Burr; Michael V Vitiello; Jasmine Zia; Monica Jarrett
Journal:  J Clin Sleep Med       Date:  2014-09-15       Impact factor: 4.062

Review 7.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

Review 8.  Current management strategies and emerging treatments for functional dyspepsia.

Authors:  Michael Camilleri; Vincenzo Stanghellini
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-05       Impact factor: 46.802

Review 9.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

Review 10.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.